Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Among patients with pulmonary arterial hypertension, once-daily treprostinil palmitil inhalation powder for 16 weeks reduced ...

Roivant Sciences Ltd. (NASDAQ: ROIV) is one of the best biotech stocks to invest in now. On June 16, Pulmovant, a Roivant ...

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

The projection represents a negative annual growth rate of 0.08%. The total number of diagnosed prevalent cases of pulmonary ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

In PAH, pulmonary rehabilitation referral and participation rates are low and are significantly affected by demographic and socioeconomic factors.

Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions ...

A comprehensive new study from the Centers for Disease Control and Prevention’s National Center for Health Statistics shows that chronic health conditions are nearly universal among Americans age 85 ...